Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016

Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016

While pioglitazone reduces insulin resistance and hepatic gluconeogenesis effectively in patients with type 2 diabetes mellitus (T2DM), these benefits remained controversial in patients with end stage renal disease (ESRD). We compared major adverse cardiac cerebrovascular events (MACCEs) and mortali...

Full description

Bibliographic Details
Main Authors: Min-Hao Lin, Huang-Yu Yang, Chieh-Li Yen, Chao-Yi Wu, Chang-Chyi Jenq, George Kuo, Wei-Sheng Peng, Jia-Rou Liu, Ya-Chung Tian, Chih-Wei Yang, Gerard F. Anderson, Lai-Chu See
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Journal of Clinical Medicine
Subjects:
Pioglitazone
DPP4-inhibitor
ESRD
cardiovascular outcome
mortality
Online Access:https://www.mdpi.com/2077-0383/9/11/3578

Similar Items

Similar Items